Calcitonin, bone-active isoflavones and vitamin D metabolites

Osteoporosis International

Volumn 9, Issue SUPPL. 2, 1999, Pages

  Gennari, C ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; IPRIFLAVONE; ISOFLAVONE DERIVATIVE; VITAMIN D DERIVATIVE;

BONE ATROPHY; BONE MASS; BONE TURNOVER; BREAST CANCER; CANCER RISK; CONFERENCE PAPER; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HUMAN; KIDNEY CALCIFICATION; NEUROLOGIC DISEASE; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SKIN MANIFESTATION; UTERUS CANCER; VAGINA BLEEDING;

BONE AND BONES; BONE DENSITY; BONE RESORPTION; CALCITONIN; FEMALE; FRACTURES, BONE; HUMANS; ISOFLAVONES; OSTEOPOROSIS, POSTMENOPAUSAL; VITAMIN D;

EID: 0032900043     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004165     Document Type: Conference Paper

References (134)

1. Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 1983;57:819-824.
2. Azria M, Copp DH, Zanelli JM. Twenty-five years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 1995;57:405-8.
3. Reginster JYL. Calcitonins: newer routes of delivery. Osteoporos Int 1993;3:53-7.
4. Overgaard K, Agnusdei D, Hansen MA, et al. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1991;72:344-9.
5. Caniggia A, Gennari C, Bencini M, et al. Calcium metabolism and calcium-47 kinetics before and after long-term thyrocalcitonin treatment in senile osteoporosis. Clin Sci 1970;38:397-407.
6. Gruber HE, Ivey JL, Baylink DJ, et al. Long-term calcitonin therapy in postmenopausal osteoporosis. Metab Clin Exp 1984;33:295-303.
7. Gennari C, Chieriehetti SM, Bigazzi S, et al. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 1985;38:455-64.
8. Mazzuoli GF, Passeri M, Gennari C, et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 1986;38:3-8.
9. Overgaard K, Riis BJ, Christiansen C, et al. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 1989; 30:435-42.
10. Thamsborg G, Storm TL, Sykulski R, et al. The effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 1991;48:302-7.
11. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556-61.
12. Gonnelli S, Cepollaro C, Pondrelli C, et al. Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: a longitudinal study. Osteoporosis Int 1996;6:303-7.
13. Overgaard K, Hansen MA, Nielsen V-AH, et al. Discontinuous calcitonin treatment of established osteoporosis: effects of withdrawal of treatment. Am J Med 1990;89:1-6.
14. Ellerington MC, Hillard TC, Whitcroft SIJ, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996;59:6-11.
15. Thamsborg G, Jensen JEB, Kollerup G, et al. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 1996;18:207-12.
16. Civitelli R, Gonnelli S, Zacchei F, et al. Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 1988;82:1268-74.
17. Nieves JW, Komar L, Cosman F, Lindsay R. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr 1998;67:18-24.
18. Singer FS, Alfred JP, Neer AM et al. An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 1972;51:2331-8.
19. Reginster JY, Gennari C, Mautalen C, et al. Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone. Scand J Rheumatol 1990;19:83-6.
20. Gruer A, Reiner HH, Lunghall S, et al. Formation of neutralizing antibodies after treatment with human calcitonin. Am J Med 1993;95:439-42.
21. Reginster JY, Denis D, Albert A, et al. One-year controlled randomization trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987;II:1481-3.
22. Gennari C. Salmon calcitonin (Miacalcic) nasal spray in prevention and treatment of osteoporosis. Clin Rheumatol 1989;8:61-5.
23. Overgaard K, Riis BJ, Christiansen C, Hansen MA. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989;299:477-9.
24. Young RL, Kumar N, Goldzieher JW. Management of menopause when estrogen cannot be used. Drugs 1990;40:220-30.
25. Meunier PJ, Delmas PD, Chaumet-Riffaud PD. Intranasal salmon calcitonin for prevention of postmenopausal bone loss: a placebo-controlled study in 109 women. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990:1861-7.
26. MacIntyre I, Whitehead MI, Banks LM, et al. Calcitonin for prevention of postmenopausal bone loss. Lancet 1991;I:900-2.
27. Gennari C, Agnusdei D, Montagnani M, et al. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 1992;50:381-3.
28. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994;55:82-6.
29. Reginster JY, Denis D, Deroisy R, et al. Long-term (3 years) prevention of trabecular bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res 1994;9:69-73.
30. Arnala I, Saastamoinen J, Alhava EM. Salmon calcitonin in the prevention of bone loss at perimenopause. Bone 1996;4:629-32.
31. Campodarve I, Drinkwater BL, Insogna KL, et al. Intranasal salmon calcitonin (INSC), 50-200 IU does not prevent bone loss in early postmenopausal women. J Bone Miner Res 1994; 9:S391.
32. Mazzuoli GF, Tabolli S, Bigi F, et al. Effects of salmon calcitonin on loss of bone mass induced by ovariectomy. Calcif Tissue Int 1990;47:209-14.
33. Grigoriou O, Papoulias I, Vitoratos N, et al. Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study. Maturitas 1997;28:147-51.
34. Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992;305:1124-8.
35. Ringe JD, Behandlung der primaren Osteoporose mit Calcium und Lachscalcitonin. Dtsch Med Wochenschr 1990;115:1176-82.
36. Peyron R, Serrurier D, Edouard C, et al. Treatment of high remodeling vertebral osteoporosis with human calcitonin: a two-year double-blind placebo controlled trial in 93 patients. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990:1430-3.
37. Rico H, Hernandez ER, Revilla M, Gomez-Castresana F. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 1992;16:131-8.
38. Rico H, Revilla M, Hernandez BR, et al. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 1995;56:181-5.
39. Burckhardt P, Burnand B. The effect of treatment with calcitonin on vertebral fracture rate in osteoporosis. Osteoporos Int 1993;3:24-30.
40. Cardona JM, Pastor E. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials. Osteoporos Int 1997;7:165-74.
41. Stock JL, Avioli LV, Baylink DJ, et al. Calcitonin-salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: three-year interim results of the PROOF study. J Bone Miner Res 1997;12:S149.
42. Levernieux J, Julien D, Caulin F. The effect of calcitonin on bone pain and acute resorption related to recent osteoporotic crush fractures: results of a double-blind and an open study. In: Cecchettin M, Segre G, editors. Calciotropic hormones and calcium metabolism. Amsterdam: Elsevier, 1986:171-8.
43. Minaire P, Mallet E, Levernieux J, et al. Immobilization bone loss: preventive effect of calcitonin in several clinical models. In: Christiansen C, Overgaard K, editors. Osteoporosis 1987. Copenhagen: Osteopress, 1987:603-5.
44. Attali G, Levernieux J, Caulin F. Recent crush fracture syndrome. Effect of salmon calcitonin: results of three double blind studies and an open study. In: Christiansen C, Overgaard K, editors. Osteoporosis 1987. Copenhagen: Osteopress, 1987:930-2.
45. Pun KK, Chan LWL. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989;11:205-9.
46. Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 1991;49:59-13.
47. Lyritis GP, Tsakalakos N, Magiasis B, et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 1991;49:369-72.
48. Combe B, Cohen C, Aubin F. Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin. Calcif Tissue Int 1997;61:10-5.
49. Gennari C, Passeri M, Chierichetti SM, Piolini M. Side effects of synthetic salmon and human calcitonin. Lancet 1983;I:594-5.
50. Wimalawansa SJ. Long-and short-term side effects and safety of calcitonin in man: a prospective study. Calcif Tissue Int 1993;52:90-3.
51. Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 1985;3:155-7.
52. Granata Q, Amato A, Salvati R, Barberis F. Activity of salmon calcitonin in senile osteoporosis. Curr Ther Res 1991;49:784-91.
53. Foti R, Martorana U, Broggini M. Long-term tolerability of nasal spray formulation of salmon calcitonin. Curr Ther Res 1995;56:429-35.
54. Brandi ML. Flavonoids: biochemical effects and therapeutic applications. Bone Min 1992;19:S3-14.
55. Brandi ML, Gennari C. Ipriflavone: new insights in its mechanism of action on bone remodeling. Calcif Tissue Int 1993;52:151-2.
56. Tsuda M, Kitazaki T, Itoh T, Fujita T. The effect of ipriflavone (TC-80) on bone resorption in tissue culture. J Bone Miner Res 1986;1:207-12.
57. Morita I, Sakaguchi K, Kurachi T, Murota SI. Ipriflavone inhibits murine osteoclast formation in vitro. Calcif Tissue Int 1992;51:57-10.
58. Notoya K, Yoshida K, Taketomi S, Yamazaki I, Kumegawa M. Inhibitory effect of ipriflavone on pit formation in mouse unfractionated bone cells. Calcif Tissue Int 1992;51:S3-6.
59. Bonucci E, Ballanti P, Martelli A, et al. Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of rats. Calcif Tissue Int 1992;50:314-9.
60. Notoya K, Tsukuda R, Yoshida K, Taketomi S. Stimulatory effect of ipriflavone on formation of bone-like tissue in rat bone marrow stromal cell culture. Calcif Tissue Int 1992;51:516-20.
61. Benvenuti S, Tanini A, Frediani U, et al. Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J Bone Miner Res 1991;6:987-96.
62. Kakai Y, Kawase T, Nakano T, et al. Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells. Calcif Tissue Int 1992;51:S11-15.
63. Cheng SL, Zhang SF, Nelson TL, et al. Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites. Calcif Tissue Int 1994;55:356-62.
64. Benvenuti S, Petilli M, Frediani U, et al. Binding and bioeffects of ipriflavone on a human preosteoclastic cell line. Biochem Biophys Res Commun 1994;201:1084-9.
65. Miyauchi A, Notoya K, Taketomi S, et al. Novel ipriflavone receptors coupled to calcium influx regulate osteoclast differentiation and function. Endocrinology 1996;137:3544-50.
66. Cecchini MG, Fleisch H, Muhlbauer RC. Ipriflavone inhibits bone resorption in intact and in ovariectomized rats. Calcif Tissue Int 1997;61:59-11.
67. Arjmandi BH, Khan DA, Juma SS, Svanborg A. The ovarian hormone deficiency-induced hypercholesterolemia is reversed by soy protein and the synthetic isoflavone, ipriflavone. Nutr Res 1997;17:885-94.
68. Ghezzo C, Cadel S, Borelli G, et al. Ipriflavone does not after bone apatite crystal structure in adult male rats. Calcif Tissue Int 1996;59:496-9.
69. Civitelli R, Abbasi-jarhomi SH, Halstead LR, Dimaragonas A. Ipriflavone improves bone density and biomechanical properties of adult male rat bones. Calcif Tissue Int 1995;56:215-9.
70. Fourtillan JB, Acerbi D. Pharmacokinetics and metabolism of ipriflavone in human. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990:2151-5.
71. Matsunaga T. Clinical evaluation of ipriflavone (TC-80) in patients with osteoporosis. Jpn Pharmacol Ther 1985;13:7389.
72. Sugioka T. Effectiveness and safety of TC-80 in long-term administration to patients with osteoporosis. Jpn J Clin Exp Med 1986;63:1295.
73. Agnusdei D, Zacchei F, Bigazzi S, et al. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis. Drugs Exp Clin Res 1989;15:97-104.
74. Orimo H. Effects of ipriflavone in involutional osteoporosis. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990:2156-2158.
75. Bossanyi A. Long term tolerance and efficacy of ipriflavone in the treatment of osteoporosis. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress; 1990:2168-73.
76. Agnusdei D, Camporeale A, Gonnelli S, et al. Short term treatment of Paget's disease of bone with ipriflavone. Bone Miner 1992;19:535-42.
77. Mazzuoli GF, Romagnoli E, Carnevale L, et al. Effects of ipriflavone on bone remodeling in primary hyperparathyroidism. Bone Miner 1992;19:827-33.
78. Valente M, Bufalino L, Castiglione GN, et al. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int 1994;54:377-80.
79. Adami S, Bufalino L, Cervetti R et al. Ipriflavone prevents radial bone mass loss in postmenopausal women with low bone mass over 2 years. Osteoporos Int 1997;7:119-125.
80. Agnusdei D, Crepaldi G, Isaia GC, et al. A double-blind placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int 1997;61:142-7.
81. Maugeri D, Panebianco P, Russo MS, et al. Ipriflavone-treatment of senile osteoporosis: results of a multicenter, double-blind clinical trial of 2 years. Arch Gerontol Geriatr 1994;19:253-63.
82. Passeri M, Biondi M, Costi D, et al. Effects of 2-year therapy with ipriflavone in elderly women with established osteoporosis. Ital J Miner Electrolyte Metab 1995;9:137-44.
83. Bufalino L, Abate G, Pedrazzoni M, Passeri M. Effect of 3-year treatment with ipriflavone on bone mass in women with severe osteoporosis. European Congress for Osteoporosis, Berlin, 11-15 September 1998 (abstract 255).
84. Reginster JY, Bufalino L, Christiansen C, et al. Design for an Ipriflavone Multicentre European Fracture Study. Calcif Tissue Int 1997;61:S28-32.
85. Szocsik K, Bart M, Bossany A, Nagy K. Ipriflavone in the prevention of postmenopausal osteoporosis. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress 1990:2164-7.
86. Melis GB, Paoletti AM, Cagnacci A. Ipriflavone prevents bone loss in postmenopausal women. Menopause 1996;3:27-32.
87. Gennari C, Agnusdei D, Crepaldi G, et al. Effect of ipriflavone a synthetic derivative of natural isoflavones - on bone mass loss in the early years after menopause. Menopause 1998;5:9-15.
88. Gambacciani M, Spinetti A, Cappagli B, et al. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. J Endocr Invest 1993;16:333-7.
89. Gambacciani M, Cappagli B, Piaggesi L, et al. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists. Calcif Tissue Int 1997;61:S15-8.
90. Agnusdei D, Gennari C, Bufalino L. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporos Int 1995:5:462-6.
91. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of combined low doses of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. Maturitas 1997;28:75-81.
92. Agnusdei D, Bufalino L. Efficacy of ipriflavone in established osteoporosis and long-term safety. Calcif Tissue Int 1997;61:S23-7.
93. Melis GB, Paoletti AM, Cagnacci A, et al. Lack of any estrogenic effect of ipriflavone in postmenopausal women. J Endocr Invest 1992;15:755-61.
94. 45Ca in senile osteoporosis. Acta Med Scand 1963;173:613-7.
95. Heaney RP, Barger-Lux MJ, Dowell MS, et al. Calcium absorptive effects of vitamin D and its major metabolites. J Clin Endocrinol Metab 1997;82:4111-6.
96. Nordin BEC. Calcium and osteoporosis. Nutrition 1997;13:664-86.
97. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338:777-83.
98. Fraser DR, Vitamin D. Lancet 1995;345:104-7.
99. 3 stimulates osteoblasts but not osteoclasts in osteoporosis and osteoarthritis. Calcif Tissue Int 1991; 49:168-73.
100. Caniggia A, Nuti R, Lorè F, et al. Total body absorptiometry in postmenopausal osteoporosis patients treated with 1α-hydroxylated vitamin D metabolites. Osteoporos Int 1993;3 (Supple 1):S181-5.
101. Francis RM, Boyle IT, Moniz C, et al. A comparison of the effects of alfacalcidol treatment and vitamin D supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporos Int 1996;6:284-90.
102. 3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone 1997;20:557-62.
103. 3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest 1981;11:305-9.
104. 3: short-and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis. Proc Natl Acad Sci USA 1982;79:3325-9.
105. Recker RR, Gallagher JC, Heaney RP. The metabolic effect of treatment with calcitriol in patients with postmenopausal osteoporosis. Clin Res 1984;32:406A.
106. 3, estradiol and placebo in postmenopausal osteoporosis. Acta Vitaminol Enzymol 1984;6:117-28.
107. 3 accelerate spinal bone loss? A controlled therapeutic trial in 70-year-old women. Clin Orthop 1985;192:215-21.
108. Falch JA, Ogdegaard OR, Finnanger AM, et al. Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Med Scand 1987;221:199-204.
109. Aloia JF, Waswani A, Yeh JK, et al. Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 1988;84:401-8.
110. Ott MS, Chesnut CH. Calcitriol is not effective in postmenopausal osteoporosis. Ann Intern Med 1989;110:267-74.
111. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. Ann Intern Med 1990;113:649-55.
112. Krolner B, Nielsen SP, Lund B, et al. Lumbar spine bone mineral content in post-menopausal osteoporosis. Calcif Tissue Int 1980;31:77A.
113. Christiansen C, Christiansen MS, McNair P, et al. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273-9.
114. 3) on osteoporosis: multicenter double-blind study. J Clin Exp Med 1982;123:958-73.
115. Lund B, Sorensen DH, Andersen RB, et al. Long-term treatment of senile osteopenia with 1α-hydroxycholecalciferol. In: Norman AW, Schaefer K, Grigoleit H-G, von Herrath D, editors. Vitamin D: a chemical, biochemical and clinical update. Berlin: Walter deGruyter, 1985:1039-40.
116. 3). Endocrinol Jpn 1985;32:305-15.
117. 3 or intermittent calcium infusions. Maturitas 1986;8:281-9.
118. 3. Bone Miner 1993;20:223-34.
119. 3) and calcium in osteoporosis. Clin Orthop Rel Res 1994;300:241-7.
120. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994;54:370-6.
121. 3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocr J 1996;43:211-20.
122. 3 on loss of bone mineral density immediately after artificial menopause. Endocr J 1997;44:299-304.
123. Fujita T. Studies of osteoporosis in Japan. Metabolism 1990;4:39-42.
124. Need AG, Morris HA, Horowitz M, et al. The response to calcitriol therapy in postmenopausal osteoporotic women is a function of initial calcium absorptive status. Calcif Tissue Int 1997;61:6-9.
125. Ebeling PR, Sandgrem ME, DiMagno EP, et al. Evidence of an age-related decrease in intestinal responsiveness to vitamin D: relationship between serum 1,25-dihydroxyvitamin D and intestinal vitamin D receptor concentration in normal women. J Clin Endocrinol Metab 1992;75:176-82.
126. 3 in oophorectomized women. J Clin Endocrinol Metab 1990;71:1288-93.
127. Kanis JA, McCloskey EV, de Takats D, et al. Treatment of osteoporosis with vitamin D. Osteoporos Int 1997;7:S140-6.
128. Matsuyama T, Ishii S, Tokita A, et al. Vitamin D receptor genotypes and bone mineral density. Lancet 1995;345:1238-9.
129. Gallagher JC, Riggs BL, Recker RR, Goldgar D. The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med 1989;191:287-92.
130. Tilyard MW, Spears GFS, Com B, et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357-62.
131. 3. J Bone Miner Metab 1992;10:184-8.
132. Tanizawa T, Takahashi HE, Endo N, et al. Vitamin D treatment in prevention of hip fractures. Bone 1995;16:161S.
133. 3 and renal function. Acta Med Scand 1982;211:51-4.
134. Civitelli R. The role of vitamin D metabolites in the treatment of osteoporosis. Calcif Tissue Int 1995;57:409-14.